Evidence map›Paper›PMID 31451895›Full record

ArticleVirchows Archiv : an international journal of pathology2019

Comprehensive in situ analysis of ALDH1 and SOX2 reveals increased expression of stem cell markers in high-grade serous carcinomas compared to low-grade serous carcinomas and atypical proliferative serous tumors.

Anna Katharina Fischer, Deborah L Pham, Hans Bösmüller, Claudia Lengerke, Philipp Wagner, Cornelia Bachmann, Christine Beschorner, Sven Perner, Stefan Kommoss, Falko Fend and 1 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Anna Katharina FischerInstitute of Pathology and Neuropathology, University of Tuebingen, Liebermeisterstraße 8, 72076, Tuebingen, Germany. anna.fischer@med.uni-tuebingen.de.ORCID http://orcid.org/0000-0001-5120-2065
Deborah L PhamInstitute of Pathology, Ludwigs-Maximilians University of Munich, Thalkirchner Straße 36, 80337, Munich, Germany.
Hans BösmüllerInstitute of Pathology and Neuropathology, University of Tuebingen, Liebermeisterstraße 8, 72076, Tuebingen, Germany.
Claudia LengerkeDivision of Clinical Hematology and Department of Biomedicine, University Hospital Basel, University of Basel, Petersgraben 4, 4031, Basel, Switzerland.
Philipp WagnerWomen's Hospital, University of Tuebingen, Calwerstraße 6, 72076, Tuebingen, Germany.
Cornelia BachmannWomen's Hospital, University of Tuebingen, Calwerstraße 6, 72076, Tuebingen, Germany.
Christine BeschornerInstitute of Pathology and Neuropathology, University of Tuebingen, Liebermeisterstraße 8, 72076, Tuebingen, Germany.
Sven PernerInstitute of Pathology, University Hospital Schleswig-Holstein, Campus Luebeck, 23538, Luebeck, Germany.
Stefan KommossWomen's Hospital, University of Tuebingen, Calwerstraße 6, 72076, Tuebingen, Germany.
Falko FendInstitute of Pathology and Neuropathology, University of Tuebingen, Liebermeisterstraße 8, 72076, Tuebingen, Germany.
Annette StaeblerInstitute of Pathology and Neuropathology, University of Tuebingen, Liebermeisterstraße 8, 72076, Tuebingen, Germany. annette.staebler@med.uni-tuebingen.de.
University of Tübingen · DELudwig-Maximilians-Universität München · DEUniversity Hospital Schleswig-Holstein · DEUniversity of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies have shown that re-expression of stem cell factors contribute to pathogenesis, therapy resistance, and recurrent disease in ovarian carcinomas. In this study, we compare the expression and co-expression of stem cell markers ALDH1 and SOX2 in different types of serous ovarian tumors. A total of 215 serous ovarian tumors (161 high-grade serous carcinomas (HGSC), 17 low-grade serous carcinomas (LGSC), 37 atypical proliferative serous tumors (APST)), and 10 cases of serous tubal intraepithelial carcinoma (STIC) were analyzed. Double immunostaining experiments addressed the association of cell proliferation (Ki67) with ALDH1 and the potential co-expression of SOX2 and ALDH1. The prognostic effect was analyzed in the cohort of HGSC. Expression of ALDH1and/or SOX2 was detected with increased frequency in HGSC (88.8%), compared with LGSC (70.5%) and APST (36.4%), while ALDH1 alone was significantly more frequently expressed in LGSC. The majority of all tumor types showed expression of ALDH1 and SOX2 in different cells. Only a minority of HGSC (4.6%) and STIC (20%) showed SOX2/ALDH1 co-expression in > 10% of tumor cells. Double staining also revealed that ALDH1 is associated with the non-proliferating Ki67-negative fraction consistent with a stem cell phenotype. Co-expression of ALDH1 and SOX2 or ALDH1 and Ki67 has no effect on survival. Expression of stem cell factors ALDH1 and/or SOX2 shows increased frequency in high-grade serous ovarian carcinomas compared to low-grade carcinomas and borderline tumors, supporting the concept that stem cell markers play different biological roles in low-grade versus high-grade serous neoplasia of the ovary.

Indexed as

AdultAldehyde Dehydrogenase 1 FamilyBiomarkers, TumorCystadenocarcinoma, SerousFemaleHumansIsoenzymesMiddle AgedNeoplastic Stem CellsOvarian NeoplasmsRetinal DehydrogenaseSOXB1 Transcription FactorsAldehyde Dehydrogenase 1 FamilyALDH1A1 protein, humanBiomarkers, TumorIsoenzymesRetinal DehydrogenaseSOX2 protein, humanSOXB1 Transcription FactorsALDH1Cancer stem cellsOvarian neoplasmsProliferationSOX2

Identifiers

PMID31451895
OpenAlexW2971328363

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.